MT3 and hepatocellular carcinoma: Further data mining revealed that while in untreated patients, MT3 expression decreased from early to the advanced stage of HCC, sorafenib-treated patients exhibited substantially higher MT3 expression in the intermediate and advanced stages of the disease (Fig. 2G), suggesting stimulatory activity of sorafenib on MT3 expression.